Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies

P Sharma, P Srivastava, A Seth, PN Tripathi… - Progress in …, 2019‏ - Elsevier
AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Combination drug therapy for the management of Alzheimer's disease

MT Kabir, MS Uddin, AA Mamun, P Jeandet… - International Journal of …, 2020‏ - mdpi.com
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Even though the
number of AD patients is rapidly growing, there is no effective treatment for this …

Current pharmacotherapy and multi-target approaches for Alzheimer's disease

SL Cheong, JK Tiew, YH Fong, HW Leong, YM Chan… - Pharmaceuticals, 2022‏ - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased
synaptic transmission and cerebral atrophy with appearance of amyloid plaques and …

Multi-target design strategies for the improved treatment of Alzheimer's disease

P Zhang, S Xu, Z Zhu, J Xu - European journal of medicinal chemistry, 2019‏ - Elsevier
Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and
poses a substantial burden on human health, economy, and society throughout the world …

Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease

N Kumar, V Kumar, P Anand, V Kumar… - Bioorganic & Medicinal …, 2022‏ - Elsevier
Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder which results
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …

[HTML][HTML] Memantine: Updating a rare success story in pro-cognitive therapeutics

PK Tari, CG Parsons, GL Collingridge, G Rammes - Neuropharmacology, 2024‏ - Elsevier
The great potential for NMDA receptor modulators as druggable targets in
neurodegenerative disorders has been met with limited success. Considered one of the rare …

[HTML][HTML] A molecular approach in drug development for Alzheimer's disease

S Agatonovic-Kustrin, C Kettle, DW Morton - Biomedicine & …, 2018‏ - Elsevier
An increase in dementia numbers and global trends in population aging across the world
prompts the need for new medications to treat the complex biological dysfunctions, such as …

From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology

C Albertini, A Salerno… - Medicinal Research …, 2021‏ - Wiley Online Library
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

N Guzior, A Wieckowska, D Panek… - Current medicinal …, 2015‏ - ingentaconnect.com
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The
available therapy is limited to the symptomatic treatment and its efficacy remains …

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

F Zemek, L Drtinova, E Nepovimova… - Expert opinion on …, 2014‏ - Taylor & Francis
Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for
an increasing number of people and countries. Populations suffering from AD financially …